Plague - Pipeline Review, H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Plague - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Plague - Overview
  • Plague - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Plague - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Plague - Companies Involved in Therapeutics Development
  • Plague - Drug Profiles
  • (anthrax + plague) (multivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • anthrax + plague vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Plague - Dormant Projects
  • Plague - Discontinued Products
  • Plague - Product Development Milestones
  • Featured News & Press Releases
  • Appendix

Companies Mentioned

  • Achaogen Inc
  • Aradigm Corp
  • Enesi Pharma Ltd
  • FasCure Therapeutics LLC
  • Greffex Inc
  • iBio Inc
  • Norwell Inc
  • Opal Biosciences Ltd
  • Prokarium Ltd
  • Tetraphase Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s4kkej

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900